Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 31 2016 - 4:34PM
Edgar (US Regulatory)
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
OMB APPROVAL
|
|
OMB Number: 3235-0058
|
|
Expires: August 31, 2018
|
|
Estimated average burden hours per response………………………... 2.50
|
|
|
|
SEC FILE NUMBER
|
|
001-08696
|
|
|
|
CUSIP NUMBER
|
|
|
|
(Check one):
|
|
ý
Form 10-K
o
Form 20-F
o
Form 11-K
¨
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
|
|
|
|
|
|
|
|
For Period Ended:
|
December 31, 2015
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-K
|
|
|
|
|
|
|
|
o
Transition Report on Form 20-F
|
|
|
|
|
|
|
|
o
Transition Report on Form 11-K
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-Q
|
|
|
|
|
|
|
|
o
Transition Report on Form N-SAR
|
|
|
|
|
|
|
|
For the Transition Period Ended:
|
|
|
|
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
|
|
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
Calmare Therapeutics Incorporated
______________________________________________________________________________________________
Full Name of Registrant
______________________________________________________________________________________________
Former Name if Applicable
1375 Kings Highway East, Suite 400
_______________________________________________________________________________________________
Address of Principal Executive Office
(Street and Number)
Fairfield, CT 06824
_______________________________________________________________________________________________
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
|
x
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why
Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed
time period.
CALMARE THERAPEUTICS INCORPORATED (the
“Registrant”) was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the period
ended December 31, 2015 (the “Annual Report”) by the March 30, 2016 filing date applicable to smaller reporting companies
due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. As
a result, the Registrant is still in the process of compiling required information to complete the Annual Report and its independent
registered public accounting firm requires additional time to complete its review of the financial statements for the period ended
December 31, 2015 to be incorporated in the Annual Report. The Registrant anticipates that it will file the Annual Report
no later than the fifteenth calendar day following the prescribed filing date.
|
SEC 1344 (04-09)
|
|
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
(Attach extra
Sheets if Needed)
PART IV — OTHER INFORMATION
|
(1)
|
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
|
|
Conrad Mir
|
|
(203)
|
|
368-6044
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
|
|
|
|
|
|
(2)
|
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
|
|
|
Yes
x
No
o
|
|
|
|
|
|
(3)
|
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
|
Yes
o
No
x
|
|
|
|
|
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
|
|
|
|
CALMARE
THERAPEUTICS INCORPORATED
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date:
|
|
March 31, 2016
|
|
By:
|
|
/s/
Conrad Mir
|
|
|
|
|
|
|
|
Conrad Mir CEO
|
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Apr 2023 to Apr 2024
